Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zetia/Lipitor Combo’s Ongoing Clinical Equivalence Trials May Address FDA’s Data Request, Merck Says

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA did not accept the company’s bioequivalence arguments supporting a fixed-dose combination of ezetimibe and atorvastatin. Merck believes new data that are expected to be available later this year may address the agency’s “complete response” letter.

You may also be interested in...



The SHARP “Approval”: Merck Gets Vytorin Labeling Change, But Not The CV Outcomes Claim It Sought

FDA opted against a new indication for the ezetimibe/simvastatin combination because the SHARP trial in chronic kidney disease patients did not assess the independent contributions of each drug on the observed effect. There was no indication at a November advisory committee review that issues related to the “combination rule” would pose a barrier to a new claim.

Merck On Track To File Novel Sleep Aid Suvorexant In 2012

Merck announced its potential first-in-class dual orexin receptor antagonist suvorexant successfully completed a second Phase III trial, apparently without safety concerns that led Actelion/GlaxoSmithKline to drop their DORA almorexant a year ago on Phase III results.

Merck's NDA For A Pill That Combines Zetia And Lipitor Is Bounced By FDA

Citing a need for more data, the agency refuses to file an NDA for a pill combining ezetimibe (Zetia) and atorvastatin (Pfizer's Lipitor).

Topics

Related Companies

UsernamePublicRestriction

Register

PS005028

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel